Press release
Respiratory Disorders Market to Reach US$213.12 Billion by 2033, Growing at 6.6% CAGR - Insights on Biologics, Devices & Regional Expansion
Respiratory Disorders Market
United States: Recent Industry Developments
✅ In May 2025, GSK plc announced FDA approval of Nucala (mepolizumab) as add-on maintenance treatment for adult patients with inadequately controlled COPD and eosinophilic phenotype.
✅ In March 2025, Celltrion announced FDA approval of OMLYCLO (omalizumab-igec) as the first biosimilar interchangeable with XOLAIR for moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.
✅ In September 2024, FDA approved Dupixent (dupilumab) as the first biologic for COPD with eosinophilic phenotype (noting ongoing impact into 2025 market dynamics).
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):
https://www.datamintelligence.com/download-sample/respiratory-disorders-market?sindhuri
Japan: Recent Industry Developments
✅ In March 2025, Sanofi/Regeneron's Dupixent (dupilumab) received approval in Japan as the first-ever biologic for COPD, supporting expanded biologic adoption in aging populations.
Asia-Pacific: Recent Industry Developments
✅ In June 2025, Viatris Inc. secured regulatory approval from China's NMPA for YUPELRI (revefenacin) inhalation solution, the first once-daily nebulized LAMA for maintenance treatment of COPD.
✅ Positive high-level results from Phase III KALOS and LOGOS trials announced by AstraZeneca in May 2025 for BREZTRI AEROSPHERE in uncontrolled asthma, highlighting triple-therapy advancements in the region.
Mergers & Acquisitions
✅ July 2025 - Global: Merck (MSD) announced it will acquire Verona Pharma for approximately $10 billion, adding Verona's COPD drug Ohtuvayre (ensifentrine) to strengthen its respiratory portfolio.
Technological Partnerships
Limited specific recent partnerships detailed; however, ongoing collaborations focus on biologics and digital health integration among major players like GSK, AstraZeneca, and Sanofi/Regeneron.
New Product/Service Launch
✅ Ongoing emphasis on connected inhalers, smart devices, and biologics expansions (e.g., Trelegy Ellipta and Breo Ellipta by GSK, Spiriva Respimat by Boehringer Ingelheim, Symbicort by AstraZeneca, Dupixent by Sanofi/Regeneron, Ohtuvayre by Merck/Verona Pharma).
✅ Home respiratory solutions like ResMed's AirSense 11 CPAP, Philips' DreamStation 2, and Fisher & Paykel's Optiflow systems continue to drive device innovations.
Technological Advancements in the Market
✅ October 2025 onward trends: Widespread adoption of precision therapies, connected inhalers, digital diagnostics, smart inhalers with AI-driven adherence platforms, and tele-respiratory monitoring systems.
✅ Expansion in home-based respiratory management and AI-integrated diagnostics for better patient outcomes in chronic conditions like COPD and asthma.
Funding Raised by Companies
No specific recent funding rounds detailed in the report for 2025; market growth primarily driven by established pharma investments in R&D for biologics and inhalation therapies.
Market Dynamics & Key Insights
✅ Rising incidences of asthma, COPD, and infectious respiratory diseases; increased demand for advanced inhalation therapies, biologics, and diagnostic tools.
✅ Key drivers include ageing populations, urban pollution, smoking prevalence, and shift toward home-based and digital respiratory care.
✅ North America dominates due to high prevalence, strong R&D, and regulatory approvals; Asia-Pacific fastest-growing with vast patient pools and healthcare investments.
✅ Restraints include generic competition eroding margins (e.g., generics for Advair and Spiriva).
Speak to Our Analyst and Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/respiratory-disorders-market?sindhuri
Segmentation
☛ By Disease Type
Chronic Obstructive Pulmonary Disease (COPD) dominates with 37.09% share in 2024, followed by Asthma (28.04% share in 2024), Pneumonia, Cystic Fibrosis, Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis, Tuberculosis, and Others. COPD leads due to high prevalence and biologic advancements.
☛ By Treatment Type
Therapeutics and Devices. Therapeutics (inhalers, biologics) hold major share; devices growing with home monitoring solutions.
☛ By End-User
Hospitals, Specialty Clinics, Home Care Settings, and Others. Home Care Settings expanding rapidly with digital and connected devices.
Regional Analysis
» North America leads the global respiratory disorders market, with the largest revenue share of 43.57% in 2024; driven by the U.S. with FDA approvals, high disease prevalence, advanced R&D, and reimbursement support.
» Asia-Pacific exhibits the fastest growth at a CAGR of 6.7% over the forecast period, supported by large patient populations, rising healthcare investments, air pollution, urbanization, and approvals in China/India.
» Europe shows strong demand driven by EMA approvals (e.g., Dupixent in 2024), biologics adoption, digital solutions, and aging populations in Germany, France, UK.
» The Middle East and Africa, along with South America, hold emerging potential with increasing access to therapies and diagnostics.
Buy now and enjoy a limited-time discount - limited-time offer!
https://www.datamintelligence.com/buy-now-page?report=respiratory-disorders-market&sindhuri
(Purchase 2 or more Reports and get higher discounts)
Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription
✅ Competitive Landscape
✅ Technology Innovation Tracker
✅ Export vs. Domestic Consumption Analysis
✅ Healthcare Expert Insights
✅ Digital Transformation & ROI Benchmarks
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us:
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us:
DataM Intelligence is a full-service market research and consulting firm, guiding organizations from initial insight to strategic implementation. We transform proprietary data, emerging trends, and market developments into agile, actionable solutions.
Our robust methodology powers a vast research database featuring 6,300+ syndicated and custom reports across 40+ industries. We have delivered strategic solutions to 200+ companies in 50+ countries, addressing the core research challenges that drive growth for our clients.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Respiratory Disorders Market to Reach US$213.12 Billion by 2033, Growing at 6.6% CAGR - Insights on Biologics, Devices & Regional Expansion here
News-ID: 4361314 • Views: …
More Releases from DataM Intelligence 4Market Research LLP
Smart Hospitals Market Set to Reach US$230.94 Billion by 2033 at 16.5% CAGR, Dri …
The global smart hospitals market size reached US$ 58.82 billion in 2024 is expected to reach US$ 230.94 billion by 2033, growing at a CAGR of 16.5% during the forecast period 2025-2033., according to DataM Intelligence.
United States: Recent Industry Developments
✅ In October 2025, GE HealthCare expanded its U.S. smart hospital ecosystem with AI-powered Command Center software integrated into EHR systems, partnering with Mayo Clinic and Cleveland Clinic to reduce patient…
Bioink Market Set to Reach US$1.08 Billion by 2033 at 19.8% CAGR, Driven by CELL …
The global bioink market size reached US$ 214.46 million in 2024 is expected to reach US$ 1,081.44 million by 2033, growing at a CAGR of 19.8% from 2025 to 2033., according to DataM Intelligence.
United States: Recent Industry Developments
✅ In October 2025, CELLINK (BICO Group) expanded its U.S. bioink production with a new high-viscosity GelMA-based bioink line, partnering with major bioprinting research centers to improve cell viability by 22% in 3D-printed…
Robot as a Service (RaaS) Market M&A Spotlight: Serve Robotics Acquires Diligent …
Robot as a Service (RaaS) Market Size and Forecast
DataM Intelligence has published a new research report on "Robot as a Service (RaaS) Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume,…
Bladder Cancer Vaccines Market Poised for Rapid Growth at 21.32% CAGR Amid BCG I …
The global bladder cancer vaccines market reached US$254 million in 2024, up from US$209 million in 2023, and is projected to reach US$1,446 million by 2033, growing at a robust CAGR of 21.32% from 2025 to 2033., according to DataM Intelligence.
United States: Recent Industry Developments
✅ In October 2025, Merck & Co., Inc. expanded its U.S. BCG-based bladder cancer immunotherapy production with a new TICE strain manufacturing line, partnering with major…
More Releases for COPD
Copd Drugs Market Size Analysis by Application, Type, and Region: Forecast to Co …
USA, New Jersey- According to Market Research Intellect, the global Copd Drugs market in the Internet, Communication and Technology category is projected to witness significant growth from 2025 to 2032. Market dynamics, technological advancements, and evolving consumer demand are expected to drive expansion during this period.
Because respiratory problems are becoming more common worldwide, especially among smokers and older populations, the market for COPD medications is expanding steadily. The need…
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market 2024-2030 Growth: …
Growth: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Insights :
For stakeholders, an optimistic view is shown by the thorough study of the worldwide "Chronic Obstructive Pulmonary Disease (COPD) Treatment market". The research provides specifics on the market's historical and present conditions as well as projected trends and size. Decision-makers may navigate the competitive environment and investment possibilities in the Chronic Obstructive Pulmonary Disease (COPD) Treatment market with the use of…
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market - Breathing Sol …
Newark, New Castle, USA - new report, titled Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Obstructive Pulmonary Disease…
Asthma & COPD Drugs Market - Breathe Freely, Live Fully: Empowering Respiratory …
Newark, New Castle, USA - new report, titled Asthma & COPD Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Asthma & COPD Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Asthma & COPD Drugs market. The report offers…
Copd CBD Gummies: Reviews (Shocking Facts) Copd CBD Oil "Ingredients" Pain Relie …
Copd CBD Gummies: With the increasing need for both individual and expert degrees, the stress and also stress are also enhancing. Individuals are using various methods to fight it. However, as a result of much less time for self, it is really hard. Here the natural herbs and supplements have actually discovered their way into our lives. The Copd CBD Oil are instances of super-effective natural supplements. The CBD existing…
Power Harmonica to Cure Chronic Asthma & COPD
Power Harmonica is a free reed wind musical instrument. It is small rectangular shaped musical instrument. It has 48 number of holes which makes it special and different from other harmonica's.
It's a pocket-friendly musical instrument. Power Harmonica is used as a natural treatment for many types of lung disorders and has no side effects. To play Power Harmonica there is no need of having a musical background it can be…
